Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel Monotherapy in MDD
NCT03855865Phase 3Withdrawn
- Sponsor
- Allergan
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- Peptides, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of rapastinel in major depressive disorder (MDD) (3 arms), sponsored by Allergan. Primary endpoint: Montgomery-Åsberg Depression Rating Scale Total Score at 6 weeks. Planned start Jul 2019; status: withdrawn.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03855865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03855865.